The Filing Desk

AbbVie vs TuHURA Biosciences

AbbVie ABBV · TuHURA Biosciences HURA · Biotechnology

Free cash flow was $17.8 billion at AbbVie and −$28 million at TuHURA Biosciences.

Side by side

AbbVieTuHURA Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$61.2B$0M
Revenue growth8.6%—
Revenue growth a year, last 5 years6.0%—
Gross margin70.2%—
Operating margin24.6%—
Net margin6.9%—
Free cash flow$17.8B−$28M
Free cash flow margin29.1%—
Return on capital15.7%—
Net debt to EBITDA2.7x—
Dividends and buybacks$12.6B$0M
Change in diluted share count0.0%156.8%
Last close$283.54$1.36
P/E at the last close48.8×—
Insider trades, last 12 monthssold $30.8 million—
Piotroski F-score7 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AbbVieTuHURA Biosciences
Operating margin
Percent of revenue
AbbVieTuHURA Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbbVieTuHURA Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbbVie and TuHURA Biosciences pages.